Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DaiS who wrote (18006)	1/21/1999 4:47:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

This John Dean is claiming that 60% of the ED cases are patients suffering from coronary artery disease, including high blood pressure. I doubt those figures are that high but if they are this is good news for Vivus because this is the group of at risk patients that Drs are being warned about using Viagra with "caution". IMO this group should not even be considered as Viagra candidates until more scientific studies can be conducted on Viagra in this patient group. Where is the double blind placebo/Viagra study that we are all waiting for? If Pfizer really cares about the safety of the patient why don't they put their money where their mouth is and conduct such a study? Perhaps they fear the results? They could have already completed such a study as 6 months would be sufficient time and many have been voicing their concerns since Viagra deaths began to be reported last May. Why isn't the FDA demanding such a study be conducted in light of the 200+ deaths reported thus far? We already know the answers to most of these questions. The real question is when will science and fact rule over spin?